Abstract: Absract: MTX is the most commonly used DMARDs of first choice. In comparison with other DMARDs, MTX is more effective in reducing signs and symptoms, disability and radiographic structural damage. In order to ensure the compliance and remission of patients, cost-effectiveness should be taken into consideration when choose between the biological agents and traditional DMARDs such as MTX. Searching proper biological or genetic markers predicting the safety and efficacy to MTX may optimize the treatment of RA.

Key words: rheumatoid arthritis, methotrexate, therapy, biologics